Predicted to enable antiporter activity and pyrimidine nucleotide-sugar transmembrane transporter activity. Predicted to be involved in nucleotide-sugar transmembrane transport. Predicted to act upstream of or within chondroitin sulfate biosynthetic process; embryonic skeletal system development; and pyrimidine nucleotide-sugar transmembrane transport. Predicted to be located in endoplasmic reticulum. Predicted to be active in Golgi apparatus. Human ortholog(s) of this gene implicated in schneckenbecken dysplasia. Orthologous to human SLC35D1 (solute carrier family 35 member D1); INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 6-propyl-2-thiouracil; acrylamide.
[[sodium arsenite results in increased abundance of Arsenic] co-treated with [manganese chloride results in increased abundance of Manganese]] results in increased expression of SLC35D1 mRNA and [sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SLC35D1 mRNA
[[sodium arsenite results in increased abundance of Arsenic] co-treated with [manganese chloride results in increased abundance of Manganese]] results in increased expression of SLC35D1 mRNA and [sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SLC35D1 mRNA
[Clofibrate co-treated with Acetaminophen] affects the expression of SLC35D1 mRNA and PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of SLC35D1 mRNA]
apicidin inhibits the reaction [Dexamethasone results in increased expression of SLC35D1 mRNA] and Valproic Acid inhibits the reaction [Dexamethasone results in increased expression of SLC35D1 mRNA]
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35D1 mRNA
[[sodium arsenite results in increased abundance of Arsenic] co-treated with [manganese chloride results in increased abundance of Manganese]] results in increased expression of SLC35D1 mRNA
[[sodium arsenite results in increased abundance of Arsenic] co-treated with [manganese chloride results in increased abundance of Manganese]] results in increased expression of SLC35D1 mRNA
[[sodium arsenite results in increased abundance of Arsenic] co-treated with [manganese chloride results in increased abundance of Manganese]] results in increased expression of SLC35D1 mRNA
[Clofibrate co-treated with Acetaminophen] affects the expression of SLC35D1 mRNA and PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of SLC35D1 mRNA]
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35D1 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35D1 mRNA
[[sodium arsenite results in increased abundance of Arsenic] co-treated with [manganese chloride results in increased abundance of Manganese]] results in increased expression of SLC35D1 mRNA and [sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SLC35D1 mRNA